// App-Quantinova.ai

2997 : Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Researchers

Presenter

  • Andrew Charles Perkins

Principal Investigators

  • Kate Burbury

  • Thomas Lehmann

  • David M Ross

  • Andreas Reiter

  • Vikas Gupta

  • Claire Harrison

  • Jean-Jacques Kiladjian

  • Alessandro Vannucchi

  • Marielle Wondergem

  • Robert Pack

  • Monika Wroclawska

  • Celine Wilke

  • Angela Zhang

  • Florian H. Heidel

Medical Centers

  • Australian Centre For Blood Diseases, Monash University, Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Kantonsspital St. Gallen, St. Gallen

  • Department of Haematology,Royal Adelaide Hospital and SA Pathology,Adelaide,Australia

  • Department of Hematology and Oncology, Universitätsklinikum Mannheim, Mannheim, Germany

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Université de Paris, Clinical Investigations Center, Saint-Louis hospital, APHP, Paris, France

  • Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera-Universitaria Careggi, Florence, Italy

  • VU University Medical Center, Amsterdam, Netherlands

  • Novartis AG, Basel, Switzerland

  • Universitatsklinikum Jena, Jena, Germany

Locations

  • Australia

  • Germany

  • Canada

  • United Kingdom

  • Italy

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Myelofibrosis

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • SelG1

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT04097821

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved